Catalog No.: PC-20898Not For Human Use, Lab Use Only.
RBN3143 (RBN-3143) is a potent, selective, NAD+-competitive catalytic inhibitor of PARP14 with IC50 of 4 nM, >300-fold selectivity over other ADP-ribosyltransferase (ART) family members.
RBN3143 (RBN-3143) is a potent, selective, NAD+-competitive catalytic inhibitor of PARP14 with IC50 of 4 nM, >300-fold selectivity over other ADP-ribosyltransferase (ART) family members.
RBN-3143 broadly suppressed disease phenotypes such as airway mucus, serum-IgE levels, and the accumulation of immune cells and inflammatory cytokines in the BALF in a mouse model of severe, steroid-resistant asthma.
RBN-3143 also suppressed the accumulation of alarmins TSLP, IL-33, and IL-25.
RBN-3143 is the first small molecule inhibitor of PARP14 entering clinical trials.
